オプションチェーンは、Obsidian Energyの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Obsidian Energyの市場センチメントを評価します。.

Obsidian Energy (AMEX:OBE) 株価情報, オプションチェーン

Obsidian Energy

Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.

Obsidian Energy Ltd

OBERON URANIUM CORP by OBERON URANIUM CORP.

Oberon Uranium Corp

Goldman Sachs analyst Carly Davenport downgrades WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) from Neutral to Sell and lowers the price target from $106 to $100.

News

Downgrades

Price Target

Analyst Ratings

Goldman Sachs Downgrades WEC Energy Group to Sell, Lowers Price Target to $100

WIIM

QXO shares are trading lower after the company announced the pricing of its offering of 89,887,640 shares at $22.25 per share.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended owning MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>), adding that he has always <a href="https://www.benzinga.com/quote/MP/earnings">liked the stock</a>.
Supporting his view, Baird analyst Ben Kallo, on June 17, maintained MP Materials with an Outperform rating and raised the price target from&nbsp;$30&nbsp;to&nbsp;$38.
When asked about Six Flags Entertainment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>), he said, &#8220;Don't be interested in it. I don't like the theme parks other than Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>).&#8221;
Supporting his view, Six Flags Entertainment, on May 8, reported worse-than-expected first-quarter sales results.
&#8220;I'm not going to fight anyone who wants to own a nuclear stock. I'm going to bless it even though it's up very, very big,&#8221; Cramer said when asked about BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>).
As per the recent news, BWXT, on June 16, named Kevin McCoy as chief nuclear officer to advance U.S. Navy submarine programs.
Cramer said he is again going to bless Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>). &#8220;It's the kind of company you need to deal with right now — they'll understand all the tariff problems, and they'll help you,&#8221; he added.
Lending support to his choice, Jabil posted third-quarter results on June 17 that exceeded analyst expectations for earnings per share and sales. Jabil also announced an investment of approximately $500 million over the next several years to expand its footprint in the Southeast United States.
Price Action:
<ul class="wp-block-list">
<li>Six Flags shares settled at $30.49 on Tuesday.</li>
<li>MP Materials shares dipped 4.5% to close at $34.91.</li>
<li>BWX Technologies gained 0.2% to settle at $142.31 on Tuesday.</li>
<li>Jabil shares rose 1.7% to close at $211.95.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Trading Ideas

BWXT

Why Cramer Thinks Jabil Is The Perfect Stock For A Tariff Storm

CORRECTION: Stryker Ticker Is 'SYK'

Stryker Announces FDA Clearance For Incompass Total Ankle System

Goldman Sachs analyst Carly Davenport upgrades Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) from Neutral to Buy and raises the price target from $125 to $132.

Upgrades

Goldman Sachs Upgrades Duke Energy to Buy, Raises Price Target to $132

Contineum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing.

Biotech

General

CTNM

Contineum Therapeutics Completes PrMS And Healthy Volunteer Enrollment In Phase 1b PET Trial Of PIPE-791

Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is unchanged from the same period last year.

Earnings

Earnings Misses

Novagold Resources Q2 Adj. EPS $(0.04) Misses $(0.03) Estimate

SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that it has undertaken a series of transactions to ensure compliance with Nasdaq's continued listing standards.&nbsp;&nbsp;
Last year on June 24, 2024, SeaStar Medical received a written notification from Nasdaq's Listing Qualifications Staff that it was not in compliance with the requirement to maintain a minimum market value of listed securities of $35 million as required by Nasdaq Listing Rule 5550(b)(2). After a hearing before the Nasdaq Hearings Panel (the "Panel"), the Panel granted the Company an extension through June 22, 2025, to evidence compliance with the alternative requirement of $2.5 million in stockholders' equity.
SeaStar Medical has completed the following capital transactions and operational improvements to evidence compliance with the Nasdaq equity rule:
Fundraising transactions:
<ul>
<li>On June 23, 2025, SeaStar Medical completed a $4.0 million public offering of common stock and warrants.</li>
<li>On April 25, 2025, SeaStar Medical entered into a purchase agreement with Lincoln Park Capital, pursuant to which Lincoln Park agreed to purchase up to an aggregate of $15.0 million of our common stock from time to time over a three-year term.</li>
</ul>
Revenue generation:
<ul>
<li>In the second fiscal quarter, SeaStar Medical continued to advance its business plan by increasing its customer count to six for the Company's FDA approved product, QUELIMMUNE, which is used by ICU physicians treating pediatric patients with multiple organ failure. QUELIMMUNE has been shown to reduce pediatric mortality by approximately 50% and completely relieve pediatric patients from a lifetime of dialysis. &nbsp;</li>
</ul>
Operating expense reduction:
<ul>
<li>In May 2025, SeaStar Medical began a cost cutting program that is expected to reduce operating expenses for the remainder of the current fiscal year. The Company does not anticipate that these expense reductions will have a material impact on operations. &nbsp;</li>
</ul>
Liability restructuring:
<ul>
<li>In May and June of 2025, approximately $1.2 million of employee compensation and director fee liabilities were extinguished as certain employees and directors waived their rights to bonuses and fees that had accrued but not paid. &nbsp;</li>
</ul>
Based on the above, SeaStar Medical believes it has regained compliance with the $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market.&nbsp;&nbsp; However, the Company awaits Nasdaq's formal confirmation of compliance.

SeaStar Medical Undertakes Strategic Transactions Including Fundraising Transactions, Revenue Generation, Operating Expense Reduction And Liability Restructuring, To Regain Nasdaq Compliance, Awaits Confirmation

We Energies  To Extend Operating Lives Of Units 7 And 8 At Oak Creek Power Plant Through End Of 2026, Postponing Retirement Date From End Of 2025

<ul>
<li>Initial computational analysis demonstrated that Evaxion's AI-Immunology&#x2122; platform can identify novel vaccine targets to combat Group A Streptococcus (GAS)</li>
<li>New vaccine program is added to Evaxion's pipeline under the name EVX-B4</li>
<li>Urgent need for preventive measures against GAS underscores the significant medical and commercial potential of EVX-B4</li>
<li>Addition of a novel infectious disease candidate to the pipeline is in line with Evaxion's partnership strategy</li>
</ul>
COPENHAGEN, Denmark, June 25, 2025 - Evaxion A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, initiates work to develop a new preventive vaccine against Group A Streptococcus (GAS), a bacteria causing hundreds of millions of infections globally each year. Infection carries the risk of several complications including life threatening conditions like rheumatic heart disease and necrotizing fasciitis ("flesh eating bacteria") and less severe yet serious diseases like strep throat and scarlet fever.
The new vaccine program, named EVX-B4, has been added to Evaxion's research &amp; development (R&amp;D) pipeline of cancer and infectious disease vaccine candidates. Initial computational analysis demonstrated that AI-Immunology&#x2122; can identify novel vaccine targets to combat GAS, which could pave the way for a new approach to fight the bacteria. Deploying AI-Immunology&#x2122; allows for fast and effective target discovery, design and validation, accelerating preclinical development of EVX-B4. This work will create a comprehensive preclinical data package to facilitate partnership discussions.
Adding EVX-B4 to the pipeline achieves another of Evaxion's milestones for 2025. Evaxion's R&amp;D pipeline now comprises five specified vaccine candidates for infectious diseases and three for cancer. The build-up of the pipeline supports Evaxion's partnership strategy as we increase the number of assets for out-licensing.

EVAX

Evaxion Initiates Work To Develop New Preventive Vaccine Against Group A Streptococcus; New Vaccine Program Added To Evaxion's Pipeline Under Name EVX-B4

Raymond James Ltd enters into agreement with FNZ to accelerate its digital transformation
&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4456311-1&amp;h=3952077249&amp;u=https%3A%2F%2Fwww.raymondjames.ca%2F&amp;a=Raymond+James+Ltd.">Raymond James Ltd.</a>, the largest independent financial services firm in Canada, today announced a strategic partnership with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4456311-1&amp;h=2547701680&amp;u=https%3A%2F%2Fwww.fnz.com%2F&amp;a=FNZ">FNZ</a>, a global wealth management platform provider, to deliver its next-generation wealth management platform. Under the agreement, Raymond James Ltd. will make a significant investment to accelerate the digital transformation of its wealth management infrastructure and elevate the advisor and client experience nationwide.
The partnership will see Raymond James Ltd. leverage FNZ's integrated, end-to-end wealth management platform—a deliberate and future-focused investment in modern infrastructure. Designed to deliver AI-powered capabilities, straight-through processing, and advanced digital capabilities, the FNZ platform will strengthen the Raymond James Ltd. unique value proposition.
"As a client-first organization, we took the time to engage with our advisors, branch associates and clients to define the future of wealth management," said Jamie Coulter CEO, Raymond James Ltd. "This isn't just a technology upgrade—it's a quantum leap in the support we provide our advisors in their delivery of exceptional client service. We're listening, investing, and acting to deliver smarter, more connected experiences for our partners and clients."
The new platform is built with a client-centric, digital-first design that improves efficiency, speed and personalization across the full wealth lifecycle. Advisors will gain a modern, intuitive operating environment, enabling more meaningful client engagements. Investors will benefit from improved digital experiences and real-time capabilities, all backed by the highest level of security and performance provided by the FNZ platform.
This strategic investment strengthens Raymond James Ltd.'s position as a premier destination for top-tier advisors across Canada, reinforcing its commitment to innovation, advisor enablement, and exceptional client service.
FNZ partners with more than 650 financial institutions globally on behalf of 26 million end investors and administers with more than US$ 1.7 trillion in assets. FNZ's market-leading technology and infrastructure will significantly enhance Raymond James Ltd.'s offering to advisors with greater flexibility to adapt quickly to changing markets, regulatory requirements, and investor expectations.
Blythe Masters, Group CEO of FNZ, said: "We are delighted to partner with Raymond James Ltd. to deliver a next-generation wealth management platform that will transform the advisor and client experience across Canada. North America is a key market for FNZ, and this partnership reflects our long-term commitment to investing in the region.
We're excited to bring this innovative platform to life and support Raymond James Ltd. in setting a new standard for wealth management in Canada."
Positioning itself as a leader in financial technology and innovation, Raymond James expects to invest approximately US$1 billion globally in FY2025, with a strong emphasis on information security infrastructure including its dedicated Cyber Threat Center.

Contracts

Raymond James Enters Strategic Partnership With FNZ To Deliver Its Next-generation Wealth Management Platform

Stock Split

TRNR

Interactive Strength shares are trading lower after the company announced a 1-for-10 reverse stock split.

Interactive Strength To Conduct 1-for-10 Reverse Split

SLNO

Soleno Therapeutics Highlights New Data On VYKATTM XR Extended-Release Tablets, Previously Known As DCCR, At 2025 United In Hope: International Prader-Willi Syndrome Conference

Goldman Sachs analyst Leah Jordan upgrades Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) from Sell to Neutral and raises the price target from $25 to $27.

Goldman Sachs Upgrades Kraft Heinz to Neutral, Raises Price Target to $27

Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development tools
Designation recognizes the potential of detalimogene to address significant unmet need
enGene Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>, or "enGene" or the "Company"))), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company's lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
The RMAT program is intended to expedite the development and review of regenerative medicine therapies for serious or life-threatening conditions, where preliminary clinical evidence suggests potential to address unmet medical needs. This designation provides enGene with several regulatory advantages, including early and frequent engagement with the FDA, potential for rolling review and priority review, and other benefits like Fast Track and Breakthrough Therapy designations.
"Receiving the RMAT designation highlights the promising profile of detalimogene and its potential to address the high unmet need in NMIBC," stated Ron Cooper, Chief Executive Officer of enGene. "Bladder cancer patients with limited options cannot wait, and we are enthusiastic about potentially expediting the regulatory process to bring a first-in-class treatment to patients."
The designation was based on previously disclosed preliminary results from the ongoing pivotal LEGEND study, which demonstrated compelling clinical activity and a generally favorable tolerability profile in patients with BCG-unresponsive NMIBC with CIS.
Detalimogene is designed for streamlined administration in urology clinics — including community practices, where approximately 70% of urologists provide care. The therapy is being evaluated for its ability to treat NMIBC though the non-viral stimulation of a local immune response in the bladder, presenting a potentially transformative option for patients who otherwise face limited choices beyond radical cystectomy.
About Non-Muscle Invasive Bladder Cancer (NMIBC) Non-muscle invasive bladder cancer (NMIBC) is a disease that poses a significant burden on both patients and clinics and has a massive economic impact on our healthcare system. NMIBC occurs when cancer cells grow in the tissues that line the interior of the bladder, but the cancer has not yet penetrated the muscle of the bladder wall. NMIBC can take the form of papillary outgrowths from the bladder wall, which are typically resected, or carcinoma in situ (CIS), flat, multifocal lesions that are unable to be resected, and the two can co-occur. About 75-80% of new bladder cancer diagnoses are NMIBC. Patients suffering from high-risk NMIBC who are unresponsive to the standard of care, Bacillus Calmette-Guérin (BCG), face high rates of disease recurrence (50-70%) and are subject to full removal of the bladder (cystectomy) as a curative but life-altering next step.

ENGN

enGene Holdings Announces The U.S. FDA Has Granted Regenerative Medicine Advanced Therapy Designation To Detalimogene Voraplasmid For Expedited Review In High-Risk, Non-Muscle Invasive Bladder Cancer

Fangdd Network Group Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

New eBee X units enhance capabilities across agriculture, urban planning, and strategic applications
WICHITA, Kan., June 25, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>), a leading provider of advanced drone and aerial imaging solutions, announces the sale of two additional eBee X drones to South Korea, expanding the country's installed base of AgEagle's eBee drones to more than 100 units. This milestone strengthens AgEagle's strategic partnership with South Korea and reinforces its position as a leader in the Asia-Pacific drone market.
The eBee X, AgEagle's flagship fixed-wing mapping drone, is engineered for high-precision geospatial data collection and is ideally suited for applications including surveying, mapping, and photogrammetry. This latest sale builds on a well-established fleet, further strengthening AgEagle's reputation as a trusted provider of cutting-edge unmanned aerial systems.

UAVS

AgEagle Expands South Korea Partnership With New eBee X Drone Sales, Surpassing 100 Units

OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) and Entera Bio Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTX#NASDAQ">ENTX</a>) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA.
Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Entera whereby the companies are advancing a proprietary novel dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment and as a weekly subcutaneous injection for patients with obesity, metabolic and fibrotic disorders. The oral program combines OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's proprietary N-Tab&#x2122; technology.

ENTX

OPKO Health And Entera Bio Say New Pharmacologic And Pharmacokinetic In Vivo Data For Investigational Oral OPK-88006 Tablet Treatment Selected For Presentation At ENDO 2025 Annual Meeting

Comments

Obsidian Energy

Obsidian Energy (OBE) オプション

Obsidian Energy (AMEX:OBE) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル